About US
Contact us
-
Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy BavencioPfizer and Merck KGaA are officially fourth to market with their checkpoint inhibitor avelumab—but first with approval to target a rare, aggressive form of skin cancer, Merkel cell carcinoma. Now bra2017/3/29
-
It's not just lower U.S. drug prices Trump wants. He wants the lowest, periodPresident Donald Trump is back with more drug-pricing promises. This time, he says he's aiming to push prices lower than anywhere else in the world. Speaking at a meeting with members of the Congress2017/3/29
-
FDA's orphan drug program under GAO scrutiny after senators allege abuseJust weeks after senators raised questions about the FDA's orphan drug program—and after Marathon Pharmaceuticals caught fire for an $89,000 list price on an old-turned-new orphan med—the GAO has agre2017/3/28
-
FDA signs off on Parkinson's add-on drug XadagoAn add-on Parkinson’s med already available in various countries in Europe will soon make its way to the U.S. as the FDA on Tuesday approved Newron Pharmaceuticals’ Xadago. Xadago earned the FDA thum2017/3/28
-
China proposes new FDA rules to speed up foreign drug approvalsChina's FDApublished(Chinese) a slate of suggested amendments to its foreign drug registration rules Friday, whichcould dramatically revamp the country’s pharmaceutical market landscape by eliminating2017/3/27
-
J&J chief Gorsky, in China for official summit, straddles Trump's globalism divideAmid uncertainty for pharma as President Donald Trump embarks on his quest of putting “America First,” Johnson & Johnson CEO Alex Gorsky played down the potential falloutfor his company during a C2017/3/27
-
Pierre Fabre and H-Immune to develop new cancer immunotherapiesFrench pharmaceutical company Pierre Fabre and H-Immune have entered a strategic research partnership to develop new cancer immunotherapies. The partnership will use H-Immune’s In Vitro Immunization2017/3/24
-
Emergent signs $100m BARDA contract to deliver BioThraxUS-based Emergent BioSolutions has signed a $100m contract with the Biomedical Advanced Research and Development Authority (BARDA) to deliver BioThrax (Anthrax Vaccine Adsorbed) to the Strategic Natio2017/3/24
-
PCC acquires Intrathecal Therapy business from Mallinckrodt for $203mPiramal’s wholly owned Critical Care subsidiary in the UK PCC has completed its previously announced acquisition of Intrathecal Therapy business from Mallinckrodt for $203m. PCC is engaged in the fie2017/3/23
-
Bellus Health agrees to sell Thallion to US firm Taro PharmaceuticalsBellus Health has signed an agreement to sell its wholly owned subsidiary Thallion Pharmaceuticals, including all the rights to the Shigamab drug candidate to US-based Taro Pharmaceuticals. Taro will2017/3/23